Systematic review and Meta-analysis of the efficacy and safety of Vorapaxar on atherosclerotic disease

DENG Tian-ming; JIANG Xuejun

doi:10.3969/j.issn.1671-6450.2015.04.21

Abstract：Objective To system evaluate the safety and efficacy of Vorapaxar in treatment of atherosclerotic disease. Methods Retrieved on PubMed, Embase, Cochrane Central Register of Controlled Trials, CNKI database, collected ran-domized controlled trial ( RCT) about the Vorapaxar in treatment of atherosclerotic disease since the establishment of the data-basetoOctober2014.SystematicreviewwereperformedusingRevMan5.1software.Results 5RCTswereincluded,Meta-analysis showed that:using cardiac death (CV), myocardial infarction (MI) and stroke as the composite end point event rate, group Vorapaxar’s end point event rate (OR =0.87, 95%CI 0.81-0.93, P <0.01), the major adverse cardiovascu-lar events (MACCE) incidence (OR=0.89, 95%CI 0.84-0.95, P =0.000 2), CV and the incidence of MI (OR=0.87, 95%CI 0.81-0.93, P <0.01), the incidence of MI (OR=0.85, 95%CI 0.78-0.92, P <0.01) were lower than in the placebo group, the incidence of bleeding (OR=1.48, 95%CI 1.39-1.57, P <0.01) and the incidence of intracranial hemorrhage (OR=2.36, 95%CI 1.40-3.98, P =0.001) were higher than in the placebo group.Conclusion In the treat-ment of atherosclerotic disease, although the incidence of bleeding and the incidence of intracranial hemorrhage of Vorapaxar group was significantly higher than in the placebo group, but it could significantly decrease CV, MI and stroke as the compos-ite end point event rate, also decrease the incidence of MACCE, incidence of CV and MI and the incidence rate of MI.Vora-paxar can become a new choice in the treatment of atherosclerotic disease.